World’s first CRISPR-based gene therapy approved for sickle cell anaemia
Casgevy has been approved for treating sickle cell disease and transfusion-dependent beta thalassemia patients aged 12 and older in the...
Casgevy has been approved for treating sickle cell disease and transfusion-dependent beta thalassemia patients aged 12 and older in the...
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a world-first regulatory authorisation to a medicine based on...